BIO INX Introduces New Biomaterials for Readily3D’s Volumetric 3D Printing Technology

Bioink technology firm BIO INX has teamed up with volumetric 3D printing company Readily3D to launch new biomaterials tailored for volumetric 3D bioprinting. The partnership marks a significant step in advancing bioprinting technology with the introduction of READYGEL INX, a gel-MA based bioink.

High-Performance Bioink for Volumetric Bioprinting

The READYGEL INX bioink is designed for high reproducibility and exceptional performance in volumetric bioprinting applications. This innovative ink, which is sterile and ready-to-use, is the first in a planned series of volumetric inks that BIO INX claims will ‘revolutionize’ bioprinting. The bioink simplifies the user experience by adhering to BIO INX’s “plug and print” principle, featuring pre-optimized processing parameters to streamline the bioprinting process and provide researchers with unprecedented ease of use.

Speed and Efficiency in Bioprinting

Volumetric 3D printing, which is capable of creating structures within seconds, benefits significantly from the properties of READYGEL INX. This technology utilizes tomographic 3D printing to quickly solidify photosensitive inks into three-dimensional structures using shaped light beams from multiple angles. This method allows for the production of centimeter-scale biological systems with microscale resolution in mere seconds. The light-based printing process ensures minimal shear stress on printed cells, with a low light dose (<600 mJ/cm²), making it highly compatible with cell and organoid printing.

Advancing Towards Clinical Applications

“Thanks to the speed of this technology, with the newly developed highly biocompatible resin, the futuristic idea of harvesting cells and printing directly alongside the patient in the operating room prior to reimplantation becomes an attainable reality,” said Coralie Gréant, COO at BIO INX.

Jasper Van Hoorick, CEO of BIO INX, emphasized the collaboration’s alignment with their vision of bringing bioprinting technology to clinical settings within the next decade. He stated, “Prioritizing standardization, reproducibility, and ‘turn-key’ bioprinting solutions, volumetric bioprinting marks a substantial advancement toward achieving these goals.”

Paul Delrot, CEO of Readily3D, added: “Partnering with a reputable supplier of reproducible light-based bioinks aligns with our commitment to delivering comprehensive solutions to our customers. By combining materials with high-reproducibility and high-performance systems, we are accelerating the journey towards clinical applications of bioprinting.”

This collaboration between BIO INX and Readily3D represents a significant advancement in bioprinting technology, promising to enhance the efficiency, reproducibility, and applicability of volumetric 3D bioprinting in clinical settings.